- Home
- PPBI vs ARQT Comparison
PPBI vs ARQT Comparison
Compare PPBI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBI
- ARQT
- Stock Information
- Founded
- PPBI 1983
- ARQT 2016
- Country
- PPBI United States
- ARQT United States
- Employees
- PPBI N/A
- ARQT N/A
- Industry
- PPBI Major Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- PPBI Finance
- ARQT Health Care
- Exchange
- PPBI Nasdaq
- ARQT Nasdaq
- Market Cap
- PPBI 2.2B
- ARQT 1.9B
- IPO Year
- PPBI 1997
- ARQT 2020
- Fundamental
- Price
- PPBI N/A
- ARQT $17.29
- Analyst Decision
- PPBI Buy
- ARQT Strong Buy
- Analyst Count
- PPBI 2
- ARQT 7
- Target Price
- PPBI $27.50
- ARQT $19.00
- AVG Volume (30 Days)
- PPBI 1.9M
- ARQT 1.5M
- Earning Date
- PPBI 10-23-2025
- ARQT 11-05-2025
- Dividend Yield
- PPBI 5.39%
- ARQT N/A
- EPS Growth
- PPBI N/A
- ARQT N/A
- EPS
- PPBI 1.43
- ARQT N/A
- Revenue
- PPBI $584,278,000.00
- ARQT $263,464,999.00
- Revenue This Year
- PPBI N/A
- ARQT $72.46
- Revenue Next Year
- PPBI $5.95
- ARQT $32.00
- P/E Ratio
- PPBI $17.15
- ARQT N/A
- Revenue Growth
- PPBI 48.04
- ARQT 99.50
- 52 Week Low
- PPBI $18.06
- ARQT $8.03
- 52 Week High
- PPBI $30.28
- ARQT $18.15
- Technical
- Relative Strength Index (RSI)
- PPBI 8.47
- ARQT 61.58
- Support Level
- PPBI $24.25
- ARQT $15.13
- Resistance Level
- PPBI $24.97
- ARQT $18.15
- Average True Range (ATR)
- PPBI 0.27
- ARQT 0.66
- MACD
- PPBI -2.65
- ARQT 0.14
- Stochastic Oscillator
- PPBI 0.00
- ARQT 71.80
About PPBI Pacific Premier Bancorp Inc
Pacific Premier Bancorp Inc through its subsidiaries, provides banking products and services. It offers cash management, electronic banking services, credit facilities, and retirement accounts, among others.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.